Luteolin, 3',4',5,7-tetrahydroxyflavone, a natural flavonoid component found in various Chinese herbs such as Scutellaria barbata D. Don, honeysuckle, chrysanthemum, schizonepeta, and ajuga decumbens, exhibits potential for cancer prevention and therapy. This study elucidates the molecular mechanisms by which luteolin, an active constituent of Scutellaria barbata, inhibits invasion and metastasis of hepatocellular carcinoma (HCC) cell lines both in vitro and in vivo. The oncogenic microRNA miR-6809-5p was found to be aberrantly upregulated in HCC tissues and downregulated by luteolin in HCC cells; overexpression of miR-6809-5p was able to restore the anti-HCC effects of luteolin via the miR-6809-5p/FLOT1/FAK signaling pathway. Furthermore, luteolin suppressed HCC invasion, metastasis, and epithelial-mesenchymal transition (EMT) through modulation of the PI3K/AKT/mTOR pathway, affecting markers such as E-cadherin, β-catenin, Vimentin, N-cadherin, Snail, Twist, and Slug. This research demonstrates that luteolin effectively inhibits HCC cell migration and invasion and significantly suppresses epithelial mesenchymal transition (EMT) both in vitro and in vivo.

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer associated with a poor prognosis. ICC accounts for about 10% of primary liver malignancies but with increasing incidence in recent years. Recently, some studies suggested that minimally interventional therapy can be used in the treatment of ICC. However, there are few references on interventional therapy for the clinical treatment of ICC. Herein we reported a case of a 48-year-old man who suffered from ICC. The patient was diagnosed with ICC by computerized tomography scan and pathological biopsy. The patient was completely cured by minimally interventional therapy with iodine-125 seed implantation. These results provide an important reference for the treatment option of ICC.

Objective To screen cuproptosis-relatedlncRNAs and establish a prognostic model of cuproptosis-related lncRNAs in hepatocellular carcinoma (HCC). Methods Perl and R languages were used to collate the HCC transcriptome and clinical data downloaded from the TCGA database. Cuproptosis-related lncRNAs were obtained through co-expression analysis, and the total samples were randomly divided into the Train group and the Test group. Univariate Cox regression analysis, LASSO regression and multivariate Cox analysis were used to analyze the data of Train group to establish the prognostic model of cuproptosis-related lncRNAs. The accuracy of the model was verified by principal component analysis (PCA), ROC curve, and independent prognostic analysis. GO and KEGG enrichment analysis, tumor mutation burden correlation analysis, immunocorrelation analysis and drug sensitivity analysis were conducted in depth. Results Co-expression analysis showed 258 cuproptosis-related lncRNAs, univariate Cox regression analysis showed 31 lncRNAs were correlated with HCC prognosis, and multivariate Cox analysis showed 5 lncRNAs involved in model construction. They are LINC00426, AL590705.3, SPRY4-AS1, AL031985.3, and AC002091.2. Validation analysis showed that the survival of patients in the low-risk group was significantly better than that in the high-risk group, and the model could be used as an independent prognostic factor for HCC. Immunocorrelation analysis showed that patients in the high and low-risk groups significantly differed in immune-related functions and immune-related therapy, which was consistent with the GO and KEGG enrichment analysis results. Tumor mutation burden correlation and drug sensitivity analysis can further guide the diagnosis and treatment of HCC patients. Conclusion The HCC prognostic model constructed by 5 cuproptosis-related lncRNAs has high accuracy and has a certain reference value for clinical diagnosis and treatment of HCC patients.